New Treatment Options for Relapsed/Recurrent DLBCL: Impact on Sequencing Therapeutic Choices - Episode 2
Dr Locke, Dr Hunter, Dr Lunning Share Referral Patterns in Their Practices
Medical experts from various prestigious oncology institutions drive a conversation around referral patterns in the DLBCL treatment landscape.
Video Player is loading.
Video content above is prompted by the following:
- What clinical factors do you consider for patients with R/R DLBCL who are primary refractory or experience early relapse in determining transplant eligibility?
- When CAR T-cell therapy is the best option for your patient, how does the manufacturing process time line affect your decisions?
- Are most community oncologists referring to CAR T-cell centers or keeping their patients?
- How early are patients being referred to your center (eg, second-line, third-line)?
- When do you initiate the collection/production process?
- What is the primary impetus for early referral?
- When CAR T-cell therapy is the best option for your patient, how does the manufacturing process time line affect your decisions?